ARCHIVES

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

NCI “Month” Appropriate For May, With Several Major Decisions Pending got Start Next 50 Years

May 1, 1987

Cancer Cases To Double By 2050 As U.S. Population Ages, Annual Report Says.

May 17, 2002

Abstracts of ‘Most Newsworthy’ Papers

June 3, 1977

In Brief: Beahrs, Murphy, Quan Honored By SSO; AACR Award Mulligan, Wiggler, Sporn, Witte

March 29, 1991

Investigators Plan To Interview DeVita, Mendelsohn on C225 Development

July 5, 2002

In Brief: New DCCP Director To BE Named Soon; Creech, Owens Head AACR, ASC; Carbone, Moertel Next

April 14, 1978